Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 13,170

Document Document Title
WO/2019/008119A1
The invention relates to a compound of the following formula (I), a method for producing same, the synthesis intermediates thereof, and uses thereof as a hypoxia imaging agent.  
WO/2019/009434A1
The present invention relates to: a compound that is formed by linking the α carbonyl group of aspartic acid directly or via a linker to at least 50% of all of the terminal groups of a dendritic polymer that has a plurality of terminal ...  
WO/2019/010299A1
The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel DOTA-haptens that may be complexed with a radioisotope (e.g., 225 ...  
WO/2019/010181A1
Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that masks or otherwise blocks phosphatidylserine on the pathogen cell surface.  
WO/2019/002842A1
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2019/003202A1
A method of obtaining, from a target compound, a radioisotope of a target element comprised in the target compound includes irradiating the target compound with high energy photon irradiation (gamma irradiation). Thereby the target eleme...  
WO/2019/006099A1
The present invention relates to compositions and methods for imaging and treating various diseases and disorders, including cancers. The composition of the invention can include a plurality of biodegradable micro-beads, each embedding a...  
WO/2018/233798A1
The present invention provides novel compounds that are useful as radiopharmaceuticals, imaging agents and for treatment of cancer.  
WO/2018/233574A1
Provided are an anti-PD-L1 humanized nanobody and the use thereof. In particular, provided is a nanobody of an anti-protein programmed death ligand 1 (PD-L1). The anti-PD-L1 nanobody can effectively block the binding of PD-L1 to a progra...  
WO/2018/235535A1
Provided is a production method for a radiohalogen-labeled compound, the method comprising: a step in which a radiohalogen-labeled precursor compound (S-L) including a leaving group (L) capable of nucleophilic substitution with a radioha...  
WO/2018/236931A1
Peptide compositions and methods for inhibiting neovascularization or development of pathological or aberrant blood vessels in human or other animal subjects,  
WO/2018/236115A1
The present invention relates to an 18F-labelled compound, and a use thereof. The compound selectively binds to a prostate-specific membrane antigen (PSMA), and enables the acquisition of clear prostate cancer images in a short time when...  
WO/2018/227977A1
Disclosed are a 99mTc-labelled isonitrile-containing glucose derivative of the structural general formula [99mTc-(CNDG)6]+ and a preparation method and the use. The derivative takes 99mTc+ as a central core, and the isonitrile carbon ato...  
WO/2018/232164A1
Embodiments of the methods and compositions provided herein relate to antibody drug conjugates comprising an antibody or antigen binding fragment thereof that specifically binds to human LGR5 in which the antibody or antigen binding frag...  
WO/2018/230257A1
The present invention addresses the problem of providing: a method for modifying an antibody in a specific and simple manner; and others. The present invention relates to: an IgG-binding peptide; an IgG-binding peptide modified with a cr...  
WO/2018/229083A1
The present invention relates to compounds, in particular those of formula (I) and formula (II) described herein, or pharmaceutically acceptable salts or solvates thereof, which may be used as radioligands in in vitro, ex vivo and in viv...  
WO/2018/231958A1
The invention is directed to methods for determining antigen-specific T cells generally and to T cell receptors which bind an epitope of the Wilms' tumor antigen-1 (WT1) protein specifically. The disclosure also provides polynucleotides ...  
WO/2018/226971A1
Described herein is a peptide, a multimodal peptide ligand imaging agent and methods for use in tumor targeting, tumor visualization, drug delivery and as an imaging ligand. The invention further provides for a theranostic peptide agent ...  
WO/2018/227132A1
Provided herein are, inter alia, pH-triggered compounds and compositions comprising one or more peptides that are capable of inserting into a lipid bilayer below a certain pH. Treatment, imaging, diagnostic, and other uses of such compou...  
WO/2018/224016A1
Disclosed is the use of berberine or a derivative thereof in preparing a myocardial perfusion imaging agent, specifically the use of 18F-labelled berberine or a derivative thereof in preparing a myocardial perfusion imaging agent. In vit...  
WO/2018/218696A1
Provided is a ligand compound ofα7 nicotinic acetylcholine receptor, which can be represented by any one of the following general formulas, wherein (1) represents a halogen. The ligand compound is an improved ligand compound of α7 nico...  
WO/2018/217637A1
Au(III) complexes for [18F] trifluoromethylation and methods for producing the same are disclosed. A gold complex comprises Au(CF3)2LR, wherein L comprises a solubility supporting ligand and R comprises an organic substituent. The Au(III...  
WO/2018/217528A1
Described herein are nanoprobes comprising ultrasmall aminated and cRGDY-conjugated nanoparticles labeled with Zirconium-89 (89Zr) and methods of their use. The provided compositions are renally clearable and possess suitable blood circu...  
WO/2018/215627A1
The present invention provides novel compounds that are useful as radiopharmaceuticals, imaging agents and for treatment of cancer.  
WO/2018/211092A1
The invention relates to an installation for the injection of a radioactive product (R) into a patient (P), which installation (1) comprises: - a first syringe (2) containing the radioactive product (R), the piston of which (23) cooperat...  
WO/2018/213808A1
Described herein are compositions and methods for diagnosing, imaging, and quantifying non-calcified atherosclerotic plaque. Embodiments of compositions described herein comprise mannosylated dextran compounds along with other carbohydra...  
WO/2018/212649A1
The present invention is in the field of a kit of parts comprising a radionuclide and a therapeutic compound, a medic ament comprising said kit of parts, and a method of treating disease by administering said kit of parts, in particular ...  
WO/2018/207193A1
Radiolabeled quaternary ammonium salt compounds featuring a quinoline skeleton and uses thereof in radioimaging are provided. The radiolabeled compounds are usable for determining a presence and/or level and/or distribution of an organic...  
WO/2018/208137A2
The present invention relates to bilirubin derivative particles comprising a bilirubin derivative and a metal, a use thereof, and a manufacturing method therefor. Since the bilirubin derivative particles of the present invention form coo...  
WO/2018/206188A1
The present invention relates to a method for the manufacture of highly purified 68Ge material for radiopharmaceutical purposes. The invention particularly concerns the production of 68Ge-API (API = Active Pharmaceutical Ingredient) solu...  
WO/2018/207171A1
The present invention discloses bimodal modified release fixed-dose combination (FDC) compositions and therapeutic methods for treatment of cancer by administration to a patient in need thereof of a FDC composition comprising a first act...  
WO/2018/207105A1
Described embodiments include an apparatus (20, 21), which includes a support (22), including an outer surface (24) and configured for insertion into a body of a subject. The apparatus further includes multiple atoms (26) of a radionucli...  
WO/2018/209346A1
The presently disclosed subject matter provides uses of anti-B7H3 antibodies for treating cancers in the central nervous system (CNS), including tumors metastatic to CNS, and in particular leptomeningeal carcinomatosis.  
WO/2018/204872A3
The present invention relates to conjugates including a chelating moiety of a metal complex thereof and a therapeutic or targeting moiety, methods for their production, and uses thereof. The present invention is directed to monoclonal an...  
WO/2018/204477A1
The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a ...  
WO/2018/202783A1
The present invention relates to a sterile aqueous ophthalmic solution comprising N-(N-acetylcysteinyl-)chitosan with a content of free thiol groups of from 80 to 280 umol/g polymer, for use in the treatment of a non-infectious corneal d...  
WO/2018/197893A1
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2018/201069A1
Disclosed herein is a composition comprising a plurality of liposomes having an average diameter of less than 400 nanometers, wherein the plurality of liposomes comprise: a first lipid or phospholipid; a second lipid or phospholipid whic...  
WO/2018/200802A1
A crosslinked CCN/CMC microsphere comprising a stably incorporated radionuclide. The microsphere can be prepared by droplet microfluidics and used in a method for radiation treatment comprising the administration of microspheres with inc...  
WO/2018/199607A1
The present invention relates to a composition for imaging a tumorous disease region, comprising a fluorescence- or radioactive isotope-labeled ERBB2 aptamer, wherein an ERBB2 aptamer labeled with a radioactive isotope or a phosphorescen...  
WO/2018/197490A1
The present invention provides a peptide that selectively binds ανβ6 integrin, the peptide having an amino acid sequence comprising the motif X1BnRGDLX2X3X4 ZmX5, wherein X1 is any D-amino acid, Bn is a sequence of any n amino acids, ...  
WO/2018/197451A1
A neutron activator for neutron activation of a material, the neutron activator being configured to produce neutrons from an interaction with a proton beam (7), the neutron activator comprising: - a neutron source comprising a metallic t...  
WO/2018/195302A1
Disclosed herein are anti-V-set domain containing T cell activation inhibitor 1 (VTCNl) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.  
WO/2018/192405A1
Provided is a target polypeptide compound having dual targets, comprising a TATE cyclic peptide structure, an RGD cyclic peptide structure, and a NOTA chelating group. The TATE cyclic peptide structure, the RGD cyclic peptide structure, ...  
WO/2018/193902A1
The present invention addresses the problem of providing an anti-hepatitis B virus agent with a new mechanism. Provided is an anti-hepatitis B virus agent which has, as its active ingredient, a nucleic acid comprising a microRNA sequence...  
WO/2018/192795A1
The present invention is directed to a compound comprising lutetium (II) ions, strongly coordinated by organic groups, for use in diagnoses of a disease, particularly as contrast agents in x-ray imaging. The compound inherently provides ...  
WO/2018/191360A1
Provided herein are compounds useful for binding to one or more histone deacetylase enzymes (HDACs). The present application further provides radiolabeled compounds useful as a radiotracer for position emission tomography imaging of HDAC...  
WO/2018/191376A2
The use of a class of prodrugs of 2-PMPA that alter tissue distribution of 2-PMPA to non-prostate tissues is disclosed. The presently disclosed prodrugs preferentially distribute to healthy tissues including the kidney, lacrimal glands, ...  
WO/2018/191376A3
The use of a class of prodrugs of 2-PMPA that alter tissue distribution of 2-PMPA to non-prostate tissues is disclosed. The presently disclosed prodrugs preferentially distribute to healthy tissues including the kidney, lacrimal glands, ...  
WO/2018/189560A1
The invention relates to a process for post-preparation labelling of liposomal formulations with F (fluorine) isotope, wherein a) during the preparation of the liposomal formulation, a phospholipid derivative modified by terminal alkyne ...  

Matches 1 - 50 out of 13,170